Evidence map›Paper›PMID 41618202›Full record

Trial reportBMC infectious diseases2026

Thereaputic efficacy of single dose Albendazole against Ascaris lumbricoides, prevalence of re-infection, and its associated factors among school children at Northwest Ethiopia: an open-label trial study.

Hana Misganaw, Mebratu Tamir, Yalewayker Tegegne, Zufan Yiheyis Abriham, Dereje Mengesha Berta, Bisrat Birke Teketelew, Negesse Cherie, Tsedenya Gebeyehu, Elias Chane, Abiy Ayele Angelo and 3 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hana MisganawDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia.
Mebratu TamirDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia. mebratut3@gmail.com.
Yalewayker TegegneDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia.
Zufan Yiheyis AbrihamDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia.
Dereje Mengesha BertaDepartment of Haematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Bisrat Birke TeketelewDepartment of Haematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Negesse CherieDepartment of Quality Assurance and Laboratory Management, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Tsedenya GebeyehuDepartment of Quality Assurance and Laboratory Management, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Elias ChaneDepartment of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Abiy Ayele AngeloDepartment of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Aberham AbereDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia.
Abebaw SetegnDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia.
Tegegne EshetuDepartment of Medical Parasitology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar City, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite extensive implementation of albendazole (ALB) mass drug administration to reduce Ascaris lumbricoides among school childrens, it remains a major chilhood health concern which needs close monitoring of ALB efficacy. Additionally, ALB donot prevent re-infection, and determinat for re-infection needs investigation. Thus, the study aimed to evaluate an efficacy of ALB against A.lumbricoides, re-infection rate, and their risk factors among school age childern (SAC) at Northwest Ethiopia.

methodsAn open-label trial study was conducted at Chuahit Primary School from June to September 2023. A total of 415 SAC were recruited using convenient sampling techniques. Nearly 2 g of stool were collected and screened using direct wet-mount and Keto-katz (KK) techniques at baseline. Of these, 50 school children who tested positive for A. lumbricoides were treated with a single dose (400 mg) of ALB. A cure and egg reduction rates were evaluated within 2–3 weeks post-treatment using KK techinque. Addtionally, reinfection rate of A.lumbricoides was assessed 3 months after ALB treatment by formal-ether concentration techinque. Pre-tested, semi-structured questionnaire was used to collect sciodemographic, and risk factors of re-infection. Data were entered into Epi-data (version 4.6) and exported to STATA (version 14) for analysis. Descriptive statistics, paired t-tests, bivariate and multivariate logistic regression model were performed. A P-value < 0.05 with a 95% CI was considered as significant value.

resultIn this study, the cure and egg reduction rates of a single dose of ALB against A.lumbricoides were found to be 92.3% [95% CI: 87.5%–97.2%] and 96.7% [95% CI: 87.8%-100%], respectively. Of the 46 school children considered for assessing the re-infection rate, about 34.7% [21.8% − 47.6%] were found to have been re-infected. Poor latrine utilization [AOR = 5.52; 95% CI: 1.07–28.5, P = 0.004] and finger nail trimming practice [AOR = 0.064; 95% CI: 0.009–0.42, P = 0.041] were significantly associated with A. lumbricoides re-infection.

conclusionEfficacy of single-dose ALB (400 mg) was within WHO satisfactory level against A. lumbricoides although a high re-infection rate was observed in the study area. This underscores the importance of promoting proper hygiene practice like regular fingernail trimming and toilet utilization strategies, alongside sustained MDA campaigns with ALB (400 mg) to achieve disease elimination goals.

trial registrationThis trial is retrospectively registered at www.pactr.org (number PACTR202407793260730) on July 16, 2024.

Indexed as

AlbendazoleAnthelminticsAscariasisAscaris lumbricoidesReinfectionAdolescentAnimalsChildEthiopiaFecesFemaleHumansMalePrevalenceRisk FactorsSchoolsAlbendazoleAnthelminticsAlbendazoleAscaris lumbricoidesNorthwest Ethiopia

Identifiers

PMID41618202
PMCPMC12930696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.